An Open, Single-Dose, Single-Centre, Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers
| Registry | NCT01058447, acronym ADME |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional; na, single group, masking: none, basic science |
| Enrollment | 4 (Actual) |
| Sponsor | AstraZeneca (Industry) |
| Conditions | Healthy |
| Interventions | AZD1981 (Drug) |
| Dates | start 2010-02-01, primary completion 2010-03-01, completion 2010-03-01, first posted 2010-01-28, last updated 2010-11-18 |
Related Papers Related Patents Related Grants Related Experts
All trials for Healthy All trials of AZD1981
The purpose of the study is to characterize the absorption, distribution, metabolism and excretion (ADME) of a single oral dose of \[14C\]AZD1981
| Arm | Type | Interventions | Description |
|---|---|---|---|
| 1 | Experimental | Drug: AZD1981 |
Sex: Male, ages: 50 Years to 65 Years, accepts healthy volunteers
Inclusion Criteria: * Provision of signed, written and dated informed consent prior to any study specific procedure * Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg Exclusion Criteria: * Exposed to radiation levels above background of >5 mSv in the last year, >10 mSv over the last 5 years or a cumulative total of >1 mSv per year of life * History or presence of any clinically significant disease or disorder in the opinion of the investigator * Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs or ECG at baseline in the opinion of the investigator